Baird Initiates Coverage On Spyre Therapeutics with Outperform Rating, Announces Price Target of $50
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Colleen Kusy initiates coverage on Spyre Therapeutics (NASDAQ:SYRE) with an Outperform rating and a price target of $50.
May 02, 2024 | 9:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird initiated coverage on Spyre Therapeutics with an Outperform rating and a price target of $50.
The initiation of coverage by Baird with an Outperform rating and a high price target of $50 is likely to generate positive investor sentiment towards SYRE. This bullish outlook from a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100